Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2022; 12(1):419-420. doi:10.7150/thno.68810 This issue Cite

Erratum

Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum

Libin Yan1,2*, Beichen Ding1,3*, Haoran Liu1,2, Yangjun Zhang1,2, Jin Zeng1,2, Junhui Hu1,2, Weimin Yao1,2, Gan Yu1,2, Ruihua An3, Zhiqiang Chen1,2, Zhangqun Ye1,2, Jinchun Xing4, Kefeng Xiao5, Lily Wu6, Hua Xu1,2✉

1. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;
2. Institute of Urology of Hubei Province, Wuhan, China
3. Department of Urinary Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
4. Department of Urology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
5. Department of Urology, The People's Hospital of Shenzhen City, Shenzhen, China.
6. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, USA
*These authors have contributed equally to this work

✉ Corresponding author: Hua Xu, Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Citation:
Yan L, Ding B, Liu H, Zhang Y, Zeng J, Hu J, Yao W, Yu G, An R, Chen Z, Ye Z, Xing J, Xiao K, Wu L, Xu H. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum. Theranostics 2022; 12(1):419-420. doi:10.7150/thno.68810. https://www.thno.org/v12p0419.htm
Other styles

File import instruction

Corrected-article in Theranostics, Volume 9, 8377

Citation styles

APA
Yan, L., Ding, B., Liu, H., Zhang, Y., Zeng, J., Hu, J., Yao, W., Yu, G., An, R., Chen, Z., Ye, Z., Xing, J., Xiao, K., Wu, L., Xu, H. (2022). Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum. Theranostics, 12(1), 419-420. https://doi.org/10.7150/thno.68810.

ACS
Yan, L.; Ding, B.; Liu, H.; Zhang, Y.; Zeng, J.; Hu, J.; Yao, W.; Yu, G.; An, R.; Chen, Z.; Ye, Z.; Xing, J.; Xiao, K.; Wu, L.; Xu, H. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum. Theranostics 2022, 12 (1), 419-420. DOI: 10.7150/thno.68810.

NLM
Yan L, Ding B, Liu H, Zhang Y, Zeng J, Hu J, Yao W, Yu G, An R, Chen Z, Ye Z, Xing J, Xiao K, Wu L, Xu H. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum. Theranostics 2022; 12(1):419-420. doi:10.7150/thno.68810. https://www.thno.org/v12p0419.htm

CSE
Yan L, Ding B, Liu H, Zhang Y, Zeng J, Hu J, Yao W, Yu G, An R, Chen Z, Ye Z, Xing J, Xiao K, Wu L, Xu H. 2022. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum. Theranostics. 12(1):419-420.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use